R
Rachel Glicksman
Researcher at University of Toronto
Publications - 54
Citations - 496
Rachel Glicksman is an academic researcher from University of Toronto. The author has contributed to research in topics: Radiation therapy & Medicine. The author has an hindex of 7, co-authored 31 publications receiving 314 citations. Previous affiliations of Rachel Glicksman include University Health Network & Cancer Care Ontario.
Papers
More filters
Journal ArticleDOI
Reprogramming Metabolism with Metformin Improves Tumor Oxygenation and Radiotherapy Response
Vanessa E. Zannella,Alan Dal Pra,Alan Dal Pra,Hala Muaddi,Hala Muaddi,Trevor D. McKee,Shawn Stapleton,Shawn Stapleton,Jenna Sykes,Jenna Sykes,Rachel Glicksman,Rachel Glicksman,Selim Chaib,Selim Chaib,Paul Zamiara,Paul Zamiara,Michael Milosevic,Michael Milosevic,Bradly G. Wouters,Robert G. Bristow,Robert G. Bristow,Marianne Koritzinsky,Marianne Koritzinsky +22 more
TL;DR: It is suggested that metformin may represent an effective and inexpensive means to improve radiotherapy outcome with an optimal therapeutic ratio and is associated with an independent and significant decrease in early biochemical relapse rates.
Journal ArticleDOI
Stereotactic Ablative Radiotherapy for the Management of Spinal Metastases: A Review.
Rachel Glicksman,Michael C. Tjong,Wellington Furtado Pimenta Neves-Junior,Daniel E. Spratt,Kevin L.M. Chua,Alireza Mansouri,Melvin L.K. Chua,Alejandro Berlin,Alejandro Berlin,Jeff Winter,Max Dahele,Ben J. Slotman,Mark H. Bilsky,David B. Shultz,David B. Shultz,Marcos Vinicius Calfat Maldaun,Nicholas J. Szerlip,Simon S. Lo,Yoshiya Yamada,Francisco E. Vera-Badillo,Gustavo Nader Marta,Fabio Y. Moraes +21 more
TL;DR: It is suggested that spinal SABR may be an effective treatment option for well-selected patients with spinal metastases, achieving high rates of local tumor control with moderate rates of adverse effects.
Journal ArticleDOI
Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis
Rachel Glicksman,Ur Metser,Douglass Vines,Douglass Vines,John F. Valliant,Zhihui Liu,Zhihui Liu,Peter Chung,Peter Chung,Robert G. Bristow,Antonio Finelli,Robert J. Hamilton,Neil Fleshner,Nathan Perlis,Alexandre R. Zlotta,David Green,David Green,David Green,Andrew Bayley,Andrew Bayley,Joelle Helou,Joelle Helou,Srinivas Raman,Srinivas Raman,Girish S. Kulkarni,Charles Catton,Charles Catton,Tony Lam,Rosanna Chan,Padraig Warde,Padraig Warde,Mary Gospodarowicz,Mary Gospodarowicz,David A. Jaffray,David A. Jaffray,Alejandro Berlin,Alejandro Berlin,Alejandro Berlin +37 more
TL;DR: In this paper, prostate-specific membrane antigen (PSMA)-targeted PET-MR/CT allows for earlier detection and localization of oligorecurrent-PCa, unveiling a molecularly defined state amenable to curative-intent metastasis-directed treatment (MDT).
Journal ArticleDOI
Sorafenib Increases Tumor Hypoxia in Cervical Cancer Patients Treated With Radiation Therapy: Results of a Phase 1 Clinical Study.
Michael Milosevic,Michael Milosevic,Carol A. Townsley,Naz Chaudary,Blaise A. Clarke,Blaise A. Clarke,Melania Pintilie,Stacy Fan,Rachel Glicksman,Masoom A. Haider,Masoom A. Haider,Sunmo Kim,Helen Mackay,Helen Mackay,Ivan Yeung,Ivan Yeung,Richard P. Hill,Richard P. Hill,Anthony Fyles,Anthony Fyles,Amit M. Oza,Amit M. Oza +21 more
TL;DR: Sorafenib increased tumor hypoxia, raising concern that it might impair rather than improve disease control when added to RTCT, which resulted in early closure of the study.
Journal ArticleDOI
International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone Therapy
Alejandro Berlin,Alejandro Berlin,Fabio Y. Moraes,Fabio Y. Moraes,Noelia Sanmamed,Rachel Glicksman,Rachel Glicksman,Alexander B. Koven,Osvaldo Espin-Garcia,Elton T.T. Leite,João Luis Fernandes da Silva,Rafael Gadia,Michael Nesbitt,Charles Catton,Charles Catton,Samuel D. Kaffenberger,Simpa S. Salami,Todd M. Morgan,Jason W.D. Hearn,William C. Jackson,Rohit Mehra,Peter Chung,Peter Chung,Neil Fleshner,Zachary S. Zumsteg,Robert T. Dess,Felix Y. Feng,Antonio Finelli,Daniel E. Spratt +28 more
TL;DR: This multicenter international effort independently validates the prognostic value of the intermediate risk prostate cancer subclassification in androgen deprivation treatment naïve cases across all radical treatment modalities.